medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2019, Number 3

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2019; 35 (3)

Survival in non-Hodgkin´s lymphoma patients with neurological symptoms according to the cerebrospinal fluid immunophenotype

Villegas VCA, Suárez RA, Torres LG, González MT, Martínez ELY, Gracia MEA, Arango PMC

Language: Spanish
References: 46
Page: 1-22
PDF size: 621.35 Kb.


ABSTRACT

Introduction: When non-Hodgkin lymphomas infiltrate the central nervous system increases mortality. The diagnosis of this infiltration can be made by the study of cerebrospinal fluid using flow cytometry, with a higher sensitivity than conventional cytology.
Objective: To estimate the relationship between the cellular immunophenotype of the cerebrospinal fluid and the overall survival of patients with non-Hodgkin lymphoma and neurological symptoms.
Methods: An analytical and prospective study was conducted in 15 patients with confirmed diagnosis of non-Hodgkin lymphoma and neurological symptoms, with negative cytology of the cerebrospinal fluid. Patients cared at Oncology Department of the National Institute of Oncology and Radiobiology, during the years 2017-2018. The immunophenotype was characterized by multiparametric flow cytometry.
Results: 60.0% of the patients was female and 53.4% older than 60 years. There was an overall mortality of 26.7%. 17 immunophenotypes were found, 58.9% of them was normal, 23.4% reactive and 17.7% suspected of malignancy. Overall survival advantage was obtained in patients with cerebrospinal fluid with normal immunophenotype (HR 0.04).
Conclusions: Flow cytometry could discriminate cells suspected of malignancy, in patients whose cytologies were negative. The presence in the cerebrospinal fluid of atypical cells, pleocytosis and a high lymphocyte-monocyte index were associated with a lower overall survival.


REFERENCES

  1. WHO. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. (Accedido: 03/01/18) Disponible en: http://globocan.iarc.fr/Pages/summary_table_site_sel.aspx

  2. MINSAP. Anuario estadístico de salud. 2017. La Habana, 2018. Disponible en: www.sld.cu/sitios/dne (Accedido: 03/01/18)

  3. Swerdlow, SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues (4th ed). Lyon, France: International Agency for Research on Cancer; 2017.

  4. Provencio Pulla M. Linfomas no Hodgkin. Sociedad Española de Oncología Médica. (Actualizado 23/03/2017).p.1-15. Disponible en: https://www.seom.org/es/info-sobre-el-cancer/linfoma-no-hodgkin?start=1 (Accedido: 03/01/18)

  5. Oliver AC, Irigoin MV. Valoración de riesgo de compromiso de sistema nervioso central en linfoma no Hodgkin difuso a grandes células B. Estrategias de profilaxis. Hematología. 2016; 20:29-39.

  6. Herr MM, Mohile NA, Barr PM, van Wijngaarden E, Brown EB, Rich DQ. Survival of Secondary Central Nervous System Lymphoma Patients in the Rituximab Era. Clin Lymphoma Myeloma Leuk. 2016;16(9):123-7.

  7. van der Meulen M, Bromberg JEC, Lam KH, Dammers R, Langerak AW, Doorduijn JK, et al. Flow Cytometry Shows Added Value in Diagnosing Lymphoma in Brain Biopsies. Cytometry B Clin Cytom. 2018;94(6):928–34.

  8. Ellin F, Landström J, Jerkeman M, Relander T. Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study. Blood. 2015;126(1):36-41.

  9. Qing C, Li H, Qi G, Jie C, Zhen L, Hui R, et al. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B‑cell lymphoma: a retrospective study. Chin J Cancer 2016;35:87.

  10. Ferreri AJ. Risk of CNS dissemination in extranodal lymphomas. Lancet Oncol. 2014; 15(4):159-69.

  11. Leach M, Drummond M, Doig A. Practical Flow Cytometry in Haematology Diagnosis, 1st ed. London: Wiley; 2013.p.100-46.

  12. Scott B, Douglas VC, Tihan T, Rubenstein JL, Josephson SA. A Systematic Approach to the Diagnosis of Suspected Central Nervous System Lymphoma. JAMA Neurol. 2013;70(3):311-9.

  13. Pittman M, Treese S, Chen L, Frater JL, Nguyen TT, Hassan A,et al. Utility of Flow Cytometry of Cerebrospinal Fluid as a Screening Tool in the Diagnosis of Central Nervous System Lymphoma. Arch Pathol Lab Med. 2013;137:1610-8.

  14. López D, Valle S, Ferrer AI, Coves J, Galán N, Gimeno J, et al. Complicaciones neurológicas del paciente con cáncer. Psicooncol. 2011;8(1):53-64.

  15. Hernández C, Pino SM, García A, Carnot J, Muñío J, Cepero K, et al. Caracterización de los linfomas no Hodgkin con afectación del sistema nervioso. Rev Acta Médic.a 2018;19(3):1-16.

  16. Schinstine M, Filie AC, Wilson W, Stetler-Stevenson M, Abati A. Detection of Malignant Hematopoietic Cells in Cerebral Spinal Fluid Previously Diagnosed as Atypical or Suspicious. Cancer Cytopathol. 2006;108(3):157-62.

  17. Alvarez R, Dupuis J, Plonquet A, Christov C, Copie-Bergman C, HemeryF, et al. Clinical relevance of flow cytometric immunophenotyping of the cerebrospinal fluid in patients with diffuse large B-cell lymphoma. Ann Oncol. 2012;23(5):1274–9.

  18. Peñalver FJ, de la Fuenta A, Olave MT, Orfao A, Sancho JM. Guía de GELTAMO para diagnóstico, prevención y manejo terapéutico de la afectación del Sistema Nervioso en pacientes con linfoma B difuso de célula grande. (1a. ed) Madrid: GETALMO; 2015.

  19. Han X, Ruan J, Zhang W, Zhou D, Xu D, Pei Q, et al. Prognostic implication of leucocyte subpopulations in diffuse large B-cell lymphoma. Oncotarget 2017;8(29):47790-800.

  20. Leval L, Harris NL. Variability in immunophenotype in diffuse large B-cell lymphoma and its clinical relevance. Histopathol. 2003;43:509-28.

  21. Onur I, Crane GM, Maleki Z. Cytomorphologic and Flow Cytometric Analysis of Cerebrospinal Fluid with T-Cell Lymphoma Involvement: A Retrospective Study of Rare Cases. Acta Cytologica 2015;59:325–331.

  22. Quijano S, López A, Sancho JM, Panizo C, Debén G, Castilla C, et al. Identification of Leptomeningeal Disease in Aggressive B-Cell Non-Hodgkin’s Lymphoma: Improved Sensitivity of Flow Cytometry. J Clin Oncol. 2009;27:1462-9.

  23. Cheminant M, Derrieux C, Touzart A, Schmit S, Grenier A,Trinquand A, et al.Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study. Haematologica 2016;101(3):336-45.

  24. Sang-Yong S, Seung-Tae L, Hee-Jin K, Young LO, Seok JK, Won Seog K, et al. Usefulness of Flow Cytometric Analysis for Detecting Leptomeningeal Diseases in Non-Hodgkin Lymphoma. Ann Lab Med. 2016;36:209-14.

  25. van Dongen JJ, Lhermitte L, Bottcher S, Almeida J, van der Velden VH, Flores-Montero J et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012; 26(9):1908-75.

  26. Benevolo G, Stacchini A, Spina M, Ferreri AJ, Arras M, Bellio L, et al. Results of a multicenter trial-addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. Blood. 2012;120:3222-8.

  27. Wilson WH, Bromberg JE, Stetler-Stevenson M, Steinberg SM, Martin-Martin L, Muniz C et al. Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma. Haematologica 2014;99(7):1228-35.

  28. Schroers R, Baraniskin A, Heute C, Vorgerd M, Brunn A, Kuhnhenn J, et al. Diagnosis of leptomeningeal disease in diffuse large B-cell lymphomas of the central nervous system by flow cytometry and cytopathology. Eur J Haematol 2010;85:520–8.

  29. Kim JH, Kim HJ, Na JU, Han SK, Choi PC, Shin DH. Hematologic parameters to predict negative cerebrospinal fluid examination results among neurologically intact patients who underwent lumbar puncture on suspicion of central nervous system infection. Clin Exp Emerg Med. 2017;4(1):25-31.

  30. Porrata LF, Ristow K, Habermann TM, Witzig TE, Colgan JP, Inwards DJ,et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol. 2012;157(3):321-30.

  31. Belotti A, Doni E, Bolis S, Rossini F, Casaroli I, Pezzatti S, et al. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era. Clin Lymphoma Myeloma Leuk. 2015; 15(4):208-13.

  32. Kumagai S, Tashima M, Fujikawa J, Iwasaki M, Iwamoto Y, Sueki Y, et al. Ratio of peripheral blood absolute lymphocyte count to absolute monocyte count at diagnosis is associated with progression-free survival in follicular lymphoma. Int J Hematol. 2014; 99(6):737-42.

  33. Lee F, Luque-Fernandez MA. Prognostic value of lymphocyte-to-monocyte ratio and neutrophilto-lymphocyte ratio in follicular lymphoma: a retrospective cohort study. BMJ Open 2017;7:1-8.

  34. Ho CL, Lu CS, Chen JH, Chen YG, Huang TC, Wu YY,et al. Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era. Medicine (Baltimore) 2015; 94(24):e993.

  35. Raza S, Naik S, Kancharla VP. Tafera F, Madhumati R, Kalavar MR. Dual-Positive (CD4+/CD8+) Acute Adult T-Cell Leukemia/Lymphoma Associated with Complex Karyotype and Refractory Hypercalcemia: Case Report and Literature Review. Case Rep Oncol. 2010;3:489-94.

  36. Stacchini A, Demurtas A, Aliberti S, Barreca A, Novero D, Pacchioni D. Single-Tube Flow Cytometry Assay for the Detection of Mature Lymphoid Neoplasms in Paucicellular Samples. Acta Cytologica 2016;60:385-94.

  37. Parker A, Bain B, Devereux S, Gatter K, Jack A, Matutes E, et al. Best Practice in Lymphoma Diagnosis and Reporting Specific disease appendix. London: British Committee for Standards in Haematology and Royal College of Pathologists; 2012.

  38. Avery PR, Avery AC. Molecular methods to distinguish reactive and neoplastic lymphocyte expansions and their importance in transitional neoplastic states. Vet Clin Pathol. 2004; 33(4):196-207.

  39. Rey LA, Villar LA. Linfocitos atípicos en dengue: papel en el diagnóstico y pronóstico de la enfermedad. Revisión sistemática de la literatura. Rev Cienc Salud. 2012;10(3):323-35.

  40. Nam AS, Giorgadze T, Tam W, Chadburn A. Assessment of the Utility of Cytology and Flow Cytometry of Cerebrospinal Fluid Samples in Clinical Practice. Acta Cytol. 2018;62(2):130-136. DOI: 10.1159/000487070.

  41. Cameirão L, Patussi R, Marega A, Tsukasa S, de Carvalho E, da Costa A, et al. Detection of central nervous system infiltration by Myeloid and lymphoid hematologic neoplasms Using Flow cytometry analysis: Diagnostic accuracy study. Front Med. 2018;5:70.

  42. Loghavi S, Wang SA, Medeiros LJ, Jorgensen JL, Li X, Xu-Monette ZY, et al. Immunophenotypic and Diagnostic Characterization of Angioimmunoblastic T-cell Lymphoma by Advanced Flow Cytometric Technology. Leuk Lymphoma. 2016; 57(12):2804–12.

  43. El Hentati FZ,Gruy F,Iobagiu C, Lamber C. Variability of CD3 Membrane Expression and T Cell Activation Capacity. Cytometry Part B Cytometry. 2010;78B:105-14.

  44. Platt MY, De Lelys ME, Preffer FI, Sohani AR. Flow Cytometry Is of Limited Utility in the Early Identification Of ‘‘Double-Hit’’ B-cell Lymphomas. Cytometry Part B Cytometry.2013; 84B:143-8.

  45. Robert G, Kellogg RG, Straus DC, Karmali R, Munoz LF, Byrne RW. Impact of therapeutic regimen and clinical presentation on overall survival in CNS lymphoma. Acta Neurochir. 2014;156:355-65.

  46. Gu L, Li H, Chen L, Ma X, Li X, Gao Y, et al. Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis. Oncotarget. 2016;7(22):31926-42.




2020     |     www.medigraphic.com